Novo Nordisk A/S (NVO) increased advertising spending in the U.S. by nearly $500 million for GLP-1 medications, outspending Eli Lilly on rival treatments. Year-over-year spending on Wegovy and Ozempic increased by 54% and 44%, respectively. Novo aims to defend market position against Zepbound and boost distribution through new channels.

Citi initiated coverage of Novo Nordisk A/S (NVO) with a ‘Neutral’ rating and DKK 400 price target, noting fair valuation despite high demand for obesity treatments. The global pharmaceutical company specializes in treating rare diseases, diabetes, and obesity. While NVO has investment potential, certain AI stocks offer greater upside potential with less downside risk.

Read more at Yahoo Finance: Novo Nordisk A/S (NVO) Eyes Solidifying Its Market Position with Increased Advertising Spending